New Haven, Conn. —Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven have appointed Joseph Paul Eder, MD, a leader in drug development and clinical research, to the positions of Director of Experimental Therapeutics and the Phase I Research Group. Dr. Eder joins Yale Cancer Center and Smilow Cancer Hospital from AstraZeneca, LP and the Dana Farber Cancer Institute. He will begin his new appointment at Yale on July 1, 2012.
“Dr. Eder has a unique combination of academic medicine and pharmaceutical experience, and proven leadership in early clinical trial development. This will be an asset to Yale Cancer Center’s Translational Research Program and strengthen the Center’s ability to translate our research findings to benefit patients at Smilow Cancer Hospital,” said Dr. Roy S. Herbst, MD, PhD, Chief of Medical Oncology and Associate Director for Translational Research at Yale Cancer Center and Smilow Cancer Hospital.
Currently, Dr. Eder serves as Senior Director in the Clinical Discovery Team at AstraZeneca, where his focus is on the design of Phase I clinical trials. He is also the Medical Science Director of AstraZeneca’s Boston site. Through this role, he is responsible for the medical and clinical aspects of development of agents from chemical lead identification through clinical proof of concept in Phase II clinical trials. Dr. Eder holds an appointment as an Associate Clinical Professor at Harvard Medical School.
Dr. Eder is on the Board of Directors for the International Symposium on Drug Development and on the Scientific Advisory Board for the International Symposium on Cancer Chemotherapy. He is a member of the American Society of Clinical Oncology and the American Association for Cancer Research, where he also sits on the Abstract committee and is a Clinical and Translational Research committee member. He has authored more than 100 peer-reviewed articles on early drug development and clinical trial outcomes.
Dr. Eder received his medical degree from Georgetown University School of Medicine, where he also completed his internship and residency. He completed a clinical fellowship in hematology and oncology at Beth Israel Hospital and the Dana Farber Cancer Institute, both in Boston, MA.
Yale Cancer Center is one of a select network of 41 comprehensive cancer centers in the country designated by the National Cancer Institute and the only one in Southern New England. Bringing together the resources of Smilow Cancer Hospital at Yale-New Haven and Yale School of Medicine, its mission encompasses patient care, research, cancer prevention and control, community outreach and education.